IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cells

  • Leukemia. 2023 Mar;37(3):695-698. doi: 10.1038/s41375-022-01805-9.
Jifeng Yu  #  1 ,  Song Li  #  2 ,  Dianze Chen  2 ,  Dandan Liu  2 ,  Huiqin Guo  2 ,  Chunmei Yang  2 ,  Wei Zhang  2 ,  Li Zhang  2 ,  Gui Zhao  2 ,  Xiaoping Tu  2 ,  Liang Peng  2 ,  Sijin Liu  2 ,  Xing Bai  2 ,  Yongping Song  1 ,  Zhongxing Jiang  1 ,  Ruliang Zhang  2 ,  Wenzhi Tian  3
Affiliations
  • 1. Department of Hematology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
  • 2. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd., Shanghai, 201203, China.
  • 3. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd., Shanghai, 201203, China. [email protected].
  • # Contributed equally.
PMID: 36575242 DOI: 10.1038/s41375-022-01805-9
Products